Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter, PhD, Johannes Sam, PhD, Claudia Ferrara Koller, PhD, Sarah Diggelmann, Esther Bommer, Anne Schönle, Christina Claus, PhD, Marina Bacac, PhD, Christian Klein, PhD, Pablo Umana, PhD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-134782

Published: 2020

Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134949

Published: 2020

Journal Articles

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

Mark Yan, Yi Meng Chang, Vibha Raghavan, Estella Dong, Christian Klein, PhD, Tina G Nielsen, Joseph N Paulson, Katerina Hatzi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134867

Published: 2020

Journal Articles

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Yaya Chu, PhD, Susiyan Jiang, MS, Jian Jiang, MD, Meijuan Tian, PhD, Dean Anthony Lee, MD PhD, Loui Madakamutil, Mario Q. Marcondes, MDPhD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139822

Published: 2020

Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Blood (2019) 134 (Supplement_1): 4450.

https://doi.org/10.1182/blood-2019-130121

Published: 2019

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma

Christine Bezombes, PhD, Cédric Rossi, MD, Pauline Gravelle, Julie Bordenave, Emilie Decaup, Mary Poupot, Marie Tosolini, Don-Marc Franchini, Camille Laurent, MD PhD, Renaud Morin, Jean-Michel Lagarde, Loic Ysebaert, MD PhD, Ariel Savina, Christian Klein, PhD, Patricia Perez-Galan, Jean-Jacques Fournié

Blood (2018) 132 (Supplement 1): 5381.

https://doi.org/10.1182/blood-2018-99-112404

Published: 2018

Journal Articles

Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances I n-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)

Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Christian Klein, PhD, Dean Anthony Lee, MD PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 1540.

https://doi.org/10.1182/blood.V130.Suppl_1.1540.1540

Published: 2017

Journal Articles

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

Frank Herting, PhD, Thomas Friess, PhD, Pablo Umaña, PhD, Middleton Steven, PhD, Christian Klein, PhD

Blood (2016) 128 (22): 4178.

https://doi.org/10.1182/blood.V128.22.4178.4178

Published: 2016

Journal Articles

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

Marina Bacac, PhD, Pablo Umaña, PhD, Sylvia Herter, PhD, Sara Colombetti, PhD, Johannes Sam, PhD, Marine Le Clech, Anne Freimoser-Grundschober, PhD, Marine Richard, Valeria Nicolini, PhD, Christian Gerdes, PhD, Laurent Lariviere, PhD, Christiane Neumann, PhD, Christian Klein, PhD

Blood (2016) 128 (22): 1836.

https://doi.org/10.1182/blood.V128.22.1836.1836

Published: 2016

Journal Articles

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

Hsiling Chiu, Patrick Hagner, PhD, Michael Pourdehnad, MD, Thomas Daniel, Rajesh Chopra, Anke Klippel, Christian Klein, PhD, Anjan Thakurta, Anita K. Gandhi, PhD

Blood (2015) 126 (23): 4007.

https://doi.org/10.1182/blood.V126.23.4007.4007

Published: 2015

Journal Articles

CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo

Loïc Ysebaert, MD PhD, Christian Klein, PhD, Anne Quillet-Mary, PhD

Blood (2015) 126 (23): 4157.

https://doi.org/10.1182/blood.V126.23.4157.4157

Published: 2015

Journal Articles

Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins

Aradhana Tiwari, Delphine CM Rolland, PharmD, PhD, Mona Elmacken, MD, Janet Ayello, MS, Carmella van de Ven, MA, Venkatesha Basrur, PhD, Kevin Conlon, MS, Damine Fermin, PhD, Matthew J. Barth, MD, Christian Klein, PhD, Kojo Elenitoba-Johnson, Megan S Lim, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 1550.

https://doi.org/10.1182/blood.V126.23.1550.1550

Published: 2015

Journal Articles

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Blood (2015) 126 (23): 2998.

https://doi.org/10.1182/blood.V126.23.2998.2998

Published: 2015

Journal Articles

Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?

Loic Ysebaert, MDPhD, Christian Klein, PhD, Anne Quillet-Mary, PhD

Blood (2014) 124 (21): 1980.

https://doi.org/10.1182/blood.V124.21.1980.1980

Published: 2014

Journal Articles

ADCC Induced By Monoclonal Anti-CD20 Antibodies in a 3D Follicular Lymphoma model : Signaling and Spatial Localization

Christine Bezombes, PhD, Emilie Decaup, PhD, Cedric Rossi, Pauline Gravelle, PhD, Camille Laurent, MD, Ariel Savina, PhD, Jean-Jacques Fournié, PhD, Christian Klein, PhD

Blood (2014) 124 (21): 3114.

https://doi.org/10.1182/blood.V124.21.3114.3114

Published: 2014

Journal Articles

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Sylvia Herter, PhD, Adam Palazzo, Marina Bacac, PhD, Laura Grosmaire, MS, Christian Frey, PhD, Stefan Pflanz, PhD, Jia Liu, PhD, Stacey Tannheimer, PhD, Pablo Umana, PhD, Christian Klein, PhD, Christophe Queva, PhD

Blood (2014) 124 (21): 3342.

https://doi.org/10.1182/blood.V124.21.3342.3342

Published: 2014

Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 1765.

https://doi.org/10.1182/blood.V124.21.1765.1765

Published: 2014

Journal Articles

Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity

Frank Herting, PhD, Sylvia Herter, PhD, Thomas Friess, PhD, Christian Lehmann, PhD, Marina Bacac, PhD, Markus Dangl, PhD, Christian Klein, PhD

Blood (2014) 124 (21): 1780.

https://doi.org/10.1182/blood.V124.21.1780.1780

Published: 2014

Journal Articles

Anti-Tumour Efficacy Study Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059, In Combination With The Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab (GA101) Demonstrates Superior In Vivo Efficacy Compared To ONO-4059 In Combination With Rituximab

Toshio Yoshizawa, PhD, Tomoko Yasuhiro, Joseph TP Birkett, PhD, Christian Klein, PhD, Kazuhito Kawabata, PhD

Blood (2013) 122 (21): 3069.

https://doi.org/10.1182/blood.V122.21.3069.3069

Published: 2013

NARROW

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma

Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances I n-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo

Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?

ADCC Induced By Monoclonal Anti-CD20 Antibodies in a 3D Follicular Lymphoma model : Signaling and Spatial Localization

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity

Anti-Tumour Efficacy Study Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059, In Combination With The Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab (GA101) Demonstrates Superior In Vivo Efficacy Compared To ONO-4059 In Combination With Rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only